PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Valganciclovir for the Suppression of Epstein-Barr Virus Replication.

Abstract Epstein-Barr virus (EBV) causes infectious mononucleosis and can lead to lymphoproliferative diseases. We evaluated the effects of valganciclovir on oral EBV shedding in a randomized, double-blind, placebo-controlled study. Twenty-six men received oral valganciclovir or daily placebo for 8 weeks, followed by a 2-week "washout period" and then 8 weeks of the alternative treatment. Valganciclovir reduced the proportion of days with EBV detected from 61.3% to 17.8% (relative risk, 0.28; 95% confidence interval [CI], .21-.41; P < .001), and quantity of virus detected by 0.77 logs (95% CI, .62-.91 logs; P < .001). Further investigations into the impact of valganciclovir on EBV-associated diseases are needed.
PMID
Related Publications

Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus.

Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease.

Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab.

Valganciclovir administration to kidney donors to reduce the burden of cytomegalovirus and Epstein-Barr virus transmission during transplantation.

Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial.

Authors

Mayor MeshTerms
Keywords

Epstein-Barr virus

infectious mononucleosis

posttransplant lymphoproliferative disorder

valganciclovir

viral shedding

Journal Title the journal of infectious diseases
Publication Year Start




PMID- 28838145
OWN - NLM
STAT- MEDLINE
DA  - 20170825
DCOM- 20170907
LR  - 20170907
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 216
IP  - 2
DP  - 2017 Jul 15
TI  - Valganciclovir for the Suppression of Epstein-Barr Virus Replication.
PG  - 198-202
LID - 10.1093/infdis/jix263 [doi]
AB  - Epstein-Barr virus (EBV) causes infectious mononucleosis and can lead to
      lymphoproliferative diseases. We evaluated the effects of valganciclovir on oral 
      EBV shedding in a randomized, double-blind, placebo-controlled study. Twenty-six 
      men received oral valganciclovir or daily placebo for 8 weeks, followed by a
      2-week "washout period" and then 8 weeks of the alternative treatment.
      Valganciclovir reduced the proportion of days with EBV detected from 61.3% to
      17.8% (relative risk, 0.28; 95% confidence interval [CI], .21-.41; P &lt; .001), and
      quantity of virus detected by 0.77 logs (95% CI, .62-.91 logs; P &lt; .001). Further
      investigations into the impact of valganciclovir on EBV-associated diseases are
      needed.
CI  - (c) The Author 2017. Published by Oxford University Press for the Infectious
      Diseases Society of America. All rights reserved. For permissions, e-mail:
      [email protected]
FAU - Yager, Jessica E
AU  - Yager JE
AD  - Department of Medicine, State University of New York Downstate Medical Center,
      Brooklyn.
FAU - Magaret, Amalia S
AU  - Magaret AS
AD  - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center.
AD  - Laboratory Medicine.
FAU - Kuntz, Steven R
AU  - Kuntz SR
AD  - Laboratory Medicine.
FAU - Selke, Stacy
AU  - Selke S
AD  - Laboratory Medicine.
FAU - Huang, Meei-Li
AU  - Huang ML
AD  - Laboratory Medicine.
FAU - Corey, Lawrence
AU  - Corey L
AD  - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center.
AD  - Laboratory Medicine.
AD  - Medicine.
FAU - Casper, Corey
AU  - Casper C
AD  - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center.
AD  - Medicine.
AD  - Epidemiology, University of Washington, Seattle, Washington.
FAU - Wald, Anna
AU  - Wald A
AD  - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center.
AD  - Laboratory Medicine.
AD  - Medicine.
AD  - Epidemiology, University of Washington, Seattle, Washington.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Antiviral Agents)
RN  - GCU97FKN3R (valganciclovir)
RN  - P9G3CKZ4P5 (Ganciclovir)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antiviral Agents/*administration &amp; dosage
MH  - Double-Blind Method
MH  - Ganciclovir/administration &amp; dosage/*analogs &amp; derivatives
MH  - Herpesvirus 4, Human/physiology
MH  - Humans
MH  - Infectious Mononucleosis/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Viral Load/drug effects
MH  - Virus Replication/*drug effects
MH  - Virus Shedding/*drug effects
MH  - Washington
MH  - Young Adult
OTO - NOTNLM
OT  - Epstein-Barr virus
OT  - infectious mononucleosis
OT  - posttransplant lymphoproliferative disorder
OT  - valganciclovir
OT  - viral shedding
EDAT- 2017/08/26 06:00
MHDA- 2017/09/08 06:00
CRDT- 2017/08/26 06:00
PHST- 2017/02/23 [received]
PHST- 2017/05/26 [accepted]
AID - 3858428 [pii]
AID - 10.1093/infdis/jix263 [doi]
PST - ppublish
SO  - J Infect Dis. 2017 Jul 15;216(2):198-202. doi: 10.1093/infdis/jix263.